Moderna plans to start human trials for vaccines against 15 threatening viruses and other pathogens by 2025, part of a strategy to develop shots that could be made quickly in response to a future pandemic.
The effort will include prototype vaccines against the virus that causes Middle East respiratory syndrome, a cousin of Covid-19; the Ebola and Marburg viruses; a tick-borne virus that causes Crimean-Congo hemorrhagic fever; and mosquito-borne viruses such as chikungunya and dengue fever, according to a company statement on Tuesday.
Moderna has come under criticism from vaccine advocates who say the company has been slow to ship doses of its Covid vaccine to poor countries and that patents it is pursuing in South Africa threaten access to shots.
The company is rowing back, announcing an agreement on Monday to open a vaccine plant in Kenya that will make as many as 500 million doses annually, although it didn’t specify which vaccines might be produced there.
While developing a Covid vaccine was relatively straightforward, it still took Moderna six months to choose a dose and establish safety before beginning final-stage trials.
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU